Skip to main
APYX

APYX Stock Forecast & Price Target

APYX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Apyx Medical is a surgical aesthetics provider leveraging its unique helium plasma technology to develop and market a range of cosmetic and surgical products and technologies. With its upcoming launch of the AYON Body Contouring System, anticipated label expansion for power liposuction, and a strong financial position, it is well-positioned to capitalize on the growing demand for skin tightening and body contouring treatments, particularly among GLP-1 users. The company's recent strategic initiatives, including cost reduction and streamlining of operations, also add to its positive outlook, with expectations of sustainable adj. EBITDA profitability.

Bears say

Apyx Medical is benefiting from the strong commercial adoption of its newly launched AYON Body Contouring System, which has generated strong early demand and positive surgeon feedback, while also pairing synergistically with the company's Renuvion technology. The company's strategic rebranding to Surgical Aesthetics, leaner cost structure, expanding U.S. sales, improved gross margins, and reduced losses and cash burn also support a positive outlook. However, potential risks include regulatory setbacks, slower commercialization of AYON, economic factors affecting the aesthetics market, and competitive threats.

APYX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Apyx Medical Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Apyx Medical Corp (APYX) Forecast

Analysts have given APYX a Strong Buy based on their latest research and market trends.

According to 4 analysts, APYX has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Apyx Medical Corp (APYX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.